Galmed Pharmaceuticals (GLMD) Receivables (2013 - 2024)
Galmed Pharmaceuticals (GLMD) posted quarterly Receivables of $692000.0 for Q4 2024, down 27.92% year-over-year from $960000.0 in Q1 2024, and down 27.92% quarter-over-quarter from $960000.0 in Q4 2023.
Galmed Pharmaceuticals (GLMD) Receivables (2013 - 2024) Analysis & Trends
Galmed Pharmaceuticals' Receivables history runs 12 years deep, the most recent figure standing at $692000.0 for Q4 2024.
- In Q4 2024, Receivables fell 27.92% year-over-year to $692000.0; the TTM figure through Dec 2024 stood at $692000.0 (down 27.92% YoY), while the FY2024 annual figure was $1.3 million, up 40.0% from the prior year.
- Receivables for Q4 2024 stood at $692000.0, down from $960000.0 in the prior quarter.
- The five-year high for Receivables was $812.8 million in Q4 2020, with the low at $692000.0 in Q4 2024.
- The 5-year median for Receivables is $1.1 million (2020), against an average of $136.5 million.
- The sharpest annual moves came in 2020 and 2021: Receivables soared 92792.8% in 2020, then sank 99.72% in 2021.
- Galmed Pharmaceuticals' Receivables stood at $812.8 million in 2020, then tumbled by 99.72% to $2.2 million in 2021, then tumbled by 61.87% to $858000.0 in 2022, then advanced by 11.89% to $960000.0 in 2023, then retreated by 27.92% to $692000.0 in 2024.
- Business Quant data shows GLMD's Receivables at $692000.0 in Q4 2024, $960000.0 in Q4 2023, and $858000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 692,000.00 |
| Dec 31, 2023 | 960,000.00 |
| Dec 31, 2022 | 858,000.00 |
| Dec 31, 2021 | 2.25 Mn |
| Dec 31, 2020 | 812.81 Mn |
| Jun 30, 2020 | 1.34 Mn |
| Dec 31, 2019 | 875,000.00 |
| Jun 30, 2019 | 1.41 Mn |
| Dec 31, 2018 | 436,000.00 |
| Jun 30, 2018 | 736,000.00 |
| Dec 31, 2017 | 310,000.00 |
| Jun 30, 2017 | 532,000.00 |
| Dec 31, 2016 | 568,000.00 |
| Jun 30, 2016 | 958,000.00 |
| Dec 31, 2015 | 758,000.00 |
| Dec 31, 2014 | 330,000.00 |
| Dec 31, 2013 | 32,000.00 |